# Spondylodiscitis Following Oxygen–Ozone Therapy: A Case Report of Lactobacillus iners Infection and a Systematic Literature Review

**Authors:** Calogero Velluto, Giovan Giuseppe Mazzella, Michele Inverso, Maria Ilaria Borruto, Andrea Perna, Riccardo Totti, Laura Scaramuzzo, Luca Proietti

PMC · DOI: 10.3390/diseases14030115 · Diseases · 2026-03-23

## TL;DR

A case of rare spinal infection caused by Lactobacillus iners after a minimally invasive back treatment is reported, highlighting the need for careful monitoring and targeted treatment.

## Contribution

First report of Lactobacillus iners causing spondylodiscitis after oxygen–ozone therapy in an immunocompetent patient.

## Key findings

- Lactobacillus iners was identified as a causative agent of spondylodiscitis following oxygen–ozone therapy.
- Eight cases of post-O2–O3 spondylodiscitis were identified, with varied pathogens and successful treatment outcomes.
- Clinical management included antibiotics and surgery, with favorable outcomes except one fatality.

## Abstract

Background: Oxygen–ozone (O2–O3) therapy is a minimally invasive treatment for discogenic lumbar pain. Although rare, spinal infections—specifically spondylodiscitis—have been reported following intradiscal injections. To date, Lactobacillus iners has not been described as a causative agent in this context. Case Presentation: A 55-year-old immunocompetent woman presented with progressive lumbosciatica and elevated inflammatory markers three months after intradiscal O2–O3 therapy. MRI revealed L4–L5 spondylodiscitis with paravertebral involvement. Surgical biopsy confirmed L. iners as the pathogen. She underwent decompression and received targeted intravenous antibiotics, achieving full clinical and radiological recovery. Methods: A systematic literature review was performed using PubMed, MEDLINE, and Scopus to identify reports of spondylodiscitis following oxygen–ozone therapy. Six cases were included based on predefined inclusion criteria. Results: The 8 identified cases involved a range of pathogens, including Staphylococcus aureus, Streptococcus beta-haemolyticus, Escherichia coli, Achromobacter xylosoxidans, Mycobacterium abscessus, and Streptococcus intermedius, and one culture-negative infection. Clinical presentations varied from radiculopathy to sepsis. Management strategies encompassed both conservative (antibiotics alone) and surgical approaches, depending on neurological status and abscess formation. Outcomes were favorable in all cases except one fatality. Conclusions: This report is the first to describe L. iners spondylodiscitis in an immunocompetent patient following O2–O3 therapy. Clinicians should vigilantly evaluate post-infiltration spinal infections, maintain a low threshold for imaging and biopsy, and implement pathogen-targeted antibiotic regimens, with surgical intervention as needed.

## Linked entities

- **Species:** Lactobacillus iners (taxon 147802), Staphylococcus aureus (taxon 1280), Escherichia coli (taxon 562), Achromobacter xylosoxidans (taxon 85698), Streptococcus intermedius (taxon 1338)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** neck stiffness (MESH:D006258), nerve root compression (MESH:D011843), spinal instability (MESH:D043171), edema (MESH:D004487), neurological complications (MESH:D002493), gait impairment (MESH:D020234), inflammatory (MESH:D007249), neurological deficits (MESH:D009461), disc herniation (MESH:D007405), axial pain (MESH:D010146), infectious complications (MESH:D003141), fever (MESH:D005334), quadriplegia (MESH:D011782), SD (MESH:D015299), low back and sciatic pain (MESH:D017116), neurological damage (MESH:D020196), iliopsoas abscess (MESH:D016659), epidural (MESH:D015174), sepsis (MESH:D018805), abscess (MESH:D000038), epidural abscess (MESH:D020802), VO (MESH:D010019), opportunistic infections (MESH:D009894), lumbar disc disease (MESH:C535531), spine pathologies (MESH:D016135), neural compression (MESH:D009408), dehydration (MESH:D003681), septic shock (MESH:D012772), urinary retention (MESH:D016055), injury to (MESH:D014947), infection (MESH:D007239)
- **Chemicals:** amoxicillin/clavulanic acid (MESH:D019980), cefepime (MESH:D000077723), ceftazidime (MESH:D002442), neridronate (MESH:C053389), ceftriaxone (MESH:D002443), lactic acid (MESH:D019344), vancomycin (MESH:D014640), O3 (MESH:D010126), O2 (MESH:D010100), daptomycin (MESH:D017576), prostaglandins (MESH:D011453), ciprofloxacin (MESH:D002939), metronidazole (MESH:D008795), clarithromycin (MESH:D017291), cephalosporins (MESH:D002511), O2-O3 (-)
- **Species:** Mycobacterium tuberculosis (species) [taxon 1773], Mycobacteroides abscessus (species) [taxon 36809], Homo sapiens (human, species) [taxon 9606], Lactobacillus iners (species) [taxon 147802], Escherichia coli (E. coli, species) [taxon 562], Streptococcus intermedius (species) [taxon 1338], Achromobacter xylosoxidans (species) [taxon 85698], Staphylococcus aureus (species) [taxon 1280]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13024818/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13024818/full.md

## References

29 references — full list in the complete paper: https://tomesphere.com/paper/PMC13024818/full.md

---
Source: https://tomesphere.com/paper/PMC13024818